Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bas Martijn Dalen has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Felix Zijlstra

    Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands

    9 shared publications
  • Sanne M. Snelder

    Sint Franciscus Gasthuis, Rotterdam, Netherlands

    6 shared publications
  • Jie Fen Chin

    Department of Cardiology, Erasmus MC, Cardiovascular Institute, Thorax Center , Dr. Molewaterplein 40, Rotterdam 3015 GD

    5 shared publications
  • Manuel Castro Cabezas

    Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands

    4 shared publications
  • Nadine Pouw

    Department of Clinical Chemistry, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands

    4 shared publications
  • Yaar Aga

    Department of Cardiology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands

    4 shared publications

Latest Publications

  • Open Access

    The case for targeted heart failure case finding in obesity

    by Bas M van Dalen, Praveen A Motiram, S Miruna Chitu, Geert-Jan Geersing, Rudolf A de Boer, B Daan Westenbrink

  • Open Access

    Proactive heart failure screening in obesity: design, recruitment, and baseline characteristics of the SCORHFE trial

    by Praveen A Motiram, Jie Fen Chin, Ellen V Rouwet, Nienke ter Hoeve, Jasper J Brugts, Rudolf A de Boer, Bas M van Dalen

    Background: Obesity is strongly associated with heart failure (HF), but recognition remains challenging in primary care because symptoms, physical findings, and natriuretic peptide concentrations may be difficult to interpret. Objectives: To describe the design, recruitment, baseline characteristics, and acceptability of a trial evaluating proactive multimodal HF screening in adults with obesity. Methods: Adults aged 45 years or older with obesity and no known cardiac disease were randomized 1:1 to proactive multimodal HF screening or usual care. Screening comprised medical history, physical examination, blood sampling, 12-lead electrocardiography, and transthoracic echocardiography. The primary endpoint is left ventricular dysfunction and/or acute HF hospitalization at 1 year. Results: Between March 2024 and June 2025, 746 individuals expressed interest, 629 (84.3%) underwent eligibility assessment, and 420 were randomized. Mean age was 58.3 ± 8.4 years, 295 participants (70.2%) were women, and median body mass index was 35.0 [32.4–38.0] kg/m2. Among 385 participants with available waist circumference data, 379 (98.4%) had central obesity. Ninety-seven participants (23.1%) had two or more cardiometabolic conditions. Among a random subset of 50 screened participants, 46 (92.0%) considered screening duration acceptable, 47 (94.0%) reported low procedural burden, and 46 (92.0%) supported routine implementation. Conclusions: Recruitment through primary care obesity pathways reached adults with substantial adiposity and cardiometabolic burden. Screening acceptability was high in a random subset. One-year follow-up will determine clinical and economic effects. Trial registration number: NCT06137261.

  • Open Access

    Epicardial adipose tissue thickness is associated with circulating biomarkers in individuals without known cardiac disease across a broad adiposity spectrum

    by J. F. Chin, S. Abou Kamar, P. A. Motiram, S. M. Snelder, I. Kardys, J. J. Brugts, R. A. de Boer, B. M. van Dalen

  • Open Access

    Bariatric Surgery Reduces Epicardial Adipose Tissue and is Associated with Improved Cardiac Function

    by Jie Fen Chin, Yaar S. Aga, Sabrina Abou Kamar, Sanne M Snelder, Willemien L Verloop, Isabella Kardys, Jasper J Brugts, Rudolf A. de Boer, Bas M. van Dalen

    Background Epicardial adipose tissue (EAT) has garnered interest due to its important role in obesity-related heart failure with preserved ejection fraction. However, while bariatric surgery is known to both improve cardiac function and reduce EAT, the presence of any relation between these two remains unclear. This study aims to investigate the association between EAT changes and improvement of cardiac dysfunction following bariatric surgery. Methods This prospective cohort study enrolled subjects aged 35-65years with a body mass index ≥ 35 kg/m² who underwent bariatric surgery, excluding those with known cardiac disease. Conventional transthoracic echocardiography and strain analyses were conducted before and one-year post-surgery. Improvement in cardiac function was defined as a composite outcome requiring improvement in three domains: systolic function (ejection fraction or global longitudinal strain), diastolic function (E/e’ratio or septal e’velocity), and cardiac remodeling (left atrial volume index or left ventricular mass index). Results In the 142 patients who completed one year follow-up, a significant reduction in EAT of 31% was observed (pre-surgery:4.9 ± 1.5 mm, post-surgery:3.4 ± 1.1 mm; p < 0.001). Linear regression revealed that a one-millimeter reduction in EAT thickness was independently associated with improvements in global longitudinal strain (%)(β-coefficient:0.48; 95%CI:0.06–0.90; p = 0.027) and septal e’(cm/s)(β-coefficient:0.28; 95%CI:0.02–0.54; p = 0.035). Furthermore, a one-millimeter reduction in EAT thickness increased the odds of cardiac improvement by 58% (OR:1.58: 95%CI:1.15–2.24: p = 0.007). Conclusion EAT reduction post-bariatric surgery was associated with LV function improvement one-year after bariatric surgery in individuals with obesity without established cardiac disease. Our results underscore the potential role of EAT as a marker of functional heart disease in obesity. Graphical Abstract * Improvement in cardiac function was defined as a binary composite outcome, requiring improvement in echocardiographic parameters across all three specified domains: (1) systolic function, defined as any increase in either EF or GLS (2) diastolic function, defined as any increase in septal e’ velocity or decrease in E/e’ ratio; and (3) cardiac remodeling, defined as any decrease in LAVI or LVMI. Model 1: adjusted for body mass index, age, and gender. Model 2: variables of model 1 with the addition of changes in hypertension, diabetes mellitus, and obstructive sleep apnea syndrome status. FU, follow up; BMI, body mass index; OSAS, obstructive sleep apnea syndrome; DM, diabetes mellitus type 2; HT, hypertension; EAT, epicardial adipose tissue; GLS, global longitudinal strain; LVMI, left ventricular mass index; LAVI, left atrial volume index; LASr, left atrial reservoir strain; OR, Odds Ratio; EF, Ejection Fraction; E/e’, early diastolic transmitral flow velocity/early diastolic mitral annular velocity ratio. Created with BioRender.com.


  • Top Cited Papers
    Open Access

    Challenges in the diagnosis of heart failure with preserved ejection fraction in individuals with obesity

    by Bas M. van Dalen, Jie Fen Chin, Praveen A. Motiram, Anneke Hendrix, Mireille E. Emans, Jasper J. Brugts, B. Daan Westenbrink, Rudolf A. de Boer

    The rising prevalence of obesity and its association with heart failure with preserved ejection fraction (HFpEF) highlight an urgent need for a diagnostic approach tailored to this population. Diagnosing HFpEF is hampered by the lack of a single non-invasive diagnostic criterion. While this makes a firm diagnosis of HFpEF already notoriously difficult in the general population, it is even more challenging in individuals with obesity. The challenges stem from a range of factors, including the use of body mass index as a conceptually suboptimal indicator of health risks associated with increased body mass, symptom overlap between HFpEF and obesity, limitations in physical examination, difficulties in electrocardiographic and echocardiographic evaluation, and reduced diagnostic sensitivity of natriuretic peptides in individuals with obesity. In this review, we examine these diagnostic challenges and propose a diagnostic algorithm specifically tailored to improve the accuracy and reliability of HFpEF diagnosis in this growing patient demographic. Graphical abstract Proposed obesity-adjusted HFpEF score. HFpEF, Heart failure with preserved ejection fraction. Created with BioRender.com.


  • Open Access

    Obesity and cardiovascular disease: how to solve a puzzle with so many interlocking pieces?

    by Bas M van Dalen, Jie Fen Chin

    This editorial refers to ‘Obesity and cardiovascular health’, by A. Welsh et al., https://doi.org/10.1093/eurjpc/zwae025.


  • Open Access

    Improved identification of left atrial enlargement in patients with obesity

    by Yaar Aga, Yalin Acardag, Jie Fen Chin, Daan Kroon, Sanne Marjolein Snelder, Lotte De Groot-De Laat, Ulas Biter, Felix Zijlstra, Jasper Brugts, Bas van Dalen

    Accurate standardization of left atrium volume (LAV) in patients with obesity is challenging. The aim of this study was to investigate and to examine the relation between LAV indexed to height2 and left atrial function in patients with moderate to severe obesity. Echocardiograms of patients with moderate to severe obesity (body mass index (BMI) ≥ 35 kg/m2) without known cardiac disease were analyzed. LAV was indexed to body surface area (BSA) and height2, and patients were divided into those with or without left atrial enlargement (LAE) based on normalization using either BSA (LAEbsa) or height2 (LAEh2). Using speckle tracking echocardiography, LA reservoir strain (LASr), LA conduit strain (LAScd), and LA contractile strain (LASct) were assessed as a measure of LA function. LA dysfunction was defined as LASct < 14%. A total of 142 patients were included in the analysis of whom 54.2% had LAEh2 and 18.3% LAEBSA. The LAEh2 group had significantly lower LASct (12.2% ± 3.2% vs. 13.6% ± 4.5%, p = 0.019) as compared to the patients without LAEh2. Significantly more patients with LA dysfunction would be correctly identified by LAEh2 than by LAEBSA (41.5% vs. 15.0%, p < 0.001). In patients with moderate to severe obesity, the use of LAEh2 identified significantly more patients with decreased LA function. LAVh2 should be preferred over LAVBSA in patients with moderate to severe obesity.


  • Open Access

    Potential Role of Left Atrial Strain in Estimation of Left Atrial Pressure in Patients with Chronic Heart Failure

    by Yaar S. Aga, Sabrina Abou Kamar, Jie Fen Chin, Victor. J. van Den Berg, Mihai Strachinaru, Daniel Bowen, Rene Frowijn, Martijn K. Akkerhuis, Alina A. Constantinescu, Victor Umans, et al.

    Aims: In a large proportion of heart failure with reduced ejection fraction (HFrEF) patients, echocardiographic estimation of left atrial pressure (LAP) is not possible when the ratio of the peak early left ventricular filling velocity over the late filling velocity (E/A ratio) is not available, which may occur due to several potential causes. Left atrial reservoir strain (LASr) is correlated with LV filling pressures and may serve as an alternative parameter in these patients. The aim of this study was to determine whether LASr can be used to estimate LAP in HFrEF patients in whom E/A ratio is not available. Methods and results: Echocardiograms of chronic HFrEF patients were analysed and LASr was assessed with speckle tracking echocardiography. LAP was estimated using the current ASE/EACVI algorithm. Patients were divided into those in whom LAP could be estimated using this algorithm (LAPe) and into those in whom this was not possible because E/A ratio was not available (LAPne). We assessed the prognostic value of LASr on the primary endpoint (PEP), which comprised the composite of hospitalization for the management of acute or worsened HF, left ventricular assist device implantation, cardiac transplantation, and cardiovascular death, whichever occurred first in time. We studied 153 patients with a mean age of 58 years of whom 76% men and 82% who were in NYHA class I-II. A total of 86 were in the LAPe group and 67 in the LAPne group. LASr was significantly lower in the LAPne group as compared with the LAPe group (15.8% vs. 23.8%, P < 0.001). PEP-free survival at a median follow-up of 2.5 years was 78% in LAPe versus 51% in LAPne patients. An increase in LASr was significantly associated with a reduced risk of the PEP in LAPne patients (adjusted hazard ratio: 0.91 per %, 95% confidence interval 0.84–0.98). An abnormal LASr (<18%) was associated with a five-fold increase in reaching the PEP. Conclusions: In HFrEF patients in whom echocardiographic estimation of LAP is not possible due to due to unavailability of E/A ratio, assessing LASr potentially carries added clinical and prognostic value.


  • Open Access

    Echocardiographic follow-up after cardiac rehabilitation designed for patients with obesity

    by Sanne M. Snelder, Iris Den Uijl, Madoka Sunamura, Felix Zijlstra, Nienke ter Hoeve, Bas M. van Dalen

    We hypothesize that a novel tailor-made cardiac rehabilitation (CR) program for obesity patients (OPTICARE XL) has better outcomes as compared to usual CR regarding parameters of cardiac function as measured by conventional and advanced transthoracic echocardiography. This is an open-label, randomized controlled trial. Inclusion criteria were: patients referred to CR with a body mass index (BMI) ≥30 kg/m2, and age ≥18 years with either coronary artery disease or nonvalvular atrial fibrillation. The experimental group participated in OPTICARE XL and the controls received the usual CR. Subjects randomized to OPTICARE XL received on top of usual CR behavioural therapy for a healthy diet and an active lifestyle for the first 12 weeks. Also, the exercise program was more tailored. Furthermore, a behavioural after-care program was organized with 6 meetings between weeks 13-52. Transthoracic (speckle tracking) echocardiography was performed at baseline and one-year follow-up. A total of 42 patients completed the follow-up, 21 in both groups. There was a mild but statistically significant reduction in weight over time, however, this was comparable between groups. There was no improvement observed in any of the echocardiographic parameters. In conclusion, cardiac function in obesity patients was not improved one-year after a novel tailor-made CR program (OPTICARE XL) as compared to usual CR.